Cargando…

Current Scenario of Clinical Cancer Research in Latin America and the Caribbean

In Latin America and the Caribbean (LAC), progress has been made in some national and regional cancer control initiatives, which have proved useful in reducing diagnostic and treatment initiation delays. However, there are still significant gaps, including a lack of oncology clinical trials. In this...

Descripción completa

Detalles Bibliográficos
Autores principales: Gössling, Gustavo, Rebelatto, Taiane F., Villarreal-Garza, Cynthia, Ferrigno, Ana S., Bretel, Denisse, Sala, Raul, Giacomazzi, Juliana, William, William N., Werutsky, Gustavo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9858272/
https://www.ncbi.nlm.nih.gov/pubmed/36661699
http://dx.doi.org/10.3390/curroncol30010050
_version_ 1784874057726951424
author Gössling, Gustavo
Rebelatto, Taiane F.
Villarreal-Garza, Cynthia
Ferrigno, Ana S.
Bretel, Denisse
Sala, Raul
Giacomazzi, Juliana
William, William N.
Werutsky, Gustavo
author_facet Gössling, Gustavo
Rebelatto, Taiane F.
Villarreal-Garza, Cynthia
Ferrigno, Ana S.
Bretel, Denisse
Sala, Raul
Giacomazzi, Juliana
William, William N.
Werutsky, Gustavo
author_sort Gössling, Gustavo
collection PubMed
description In Latin America and the Caribbean (LAC), progress has been made in some national and regional cancer control initiatives, which have proved useful in reducing diagnostic and treatment initiation delays. However, there are still significant gaps, including a lack of oncology clinical trials. In this article, we will introduce the current status of the region’s clinical research in cancer, with a special focus on academic cancer research groups and investigator-initiated research (IIR) initiatives. Investigators in LAC have strived to improve cancer research despite drawbacks and difficulties in funding, regulatory timelines, and a skilled workforce. Progress has been observed in the representation of this region in clinical trial development and conduct, as well as in scientific productivity. However, most oncology trials in the region have been sponsored by pharmaceutical companies, highlighting the need for increased funding from governments and private foundations. Improvements in obtaining and/or strengthening the LAC cancer research group’s financing will provide opportunities to address cancer therapies and management shortcomings specific to the region. Furthermore, by including this large, ethnic, and genetically diverse population in the world’s research agenda, one may bridge the gap in knowledge regarding the applicability of results of clinical trials now mainly conducted in populations from the Northern Hemisphere.
format Online
Article
Text
id pubmed-9858272
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-98582722023-01-21 Current Scenario of Clinical Cancer Research in Latin America and the Caribbean Gössling, Gustavo Rebelatto, Taiane F. Villarreal-Garza, Cynthia Ferrigno, Ana S. Bretel, Denisse Sala, Raul Giacomazzi, Juliana William, William N. Werutsky, Gustavo Curr Oncol Review In Latin America and the Caribbean (LAC), progress has been made in some national and regional cancer control initiatives, which have proved useful in reducing diagnostic and treatment initiation delays. However, there are still significant gaps, including a lack of oncology clinical trials. In this article, we will introduce the current status of the region’s clinical research in cancer, with a special focus on academic cancer research groups and investigator-initiated research (IIR) initiatives. Investigators in LAC have strived to improve cancer research despite drawbacks and difficulties in funding, regulatory timelines, and a skilled workforce. Progress has been observed in the representation of this region in clinical trial development and conduct, as well as in scientific productivity. However, most oncology trials in the region have been sponsored by pharmaceutical companies, highlighting the need for increased funding from governments and private foundations. Improvements in obtaining and/or strengthening the LAC cancer research group’s financing will provide opportunities to address cancer therapies and management shortcomings specific to the region. Furthermore, by including this large, ethnic, and genetically diverse population in the world’s research agenda, one may bridge the gap in knowledge regarding the applicability of results of clinical trials now mainly conducted in populations from the Northern Hemisphere. MDPI 2023-01-04 /pmc/articles/PMC9858272/ /pubmed/36661699 http://dx.doi.org/10.3390/curroncol30010050 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Gössling, Gustavo
Rebelatto, Taiane F.
Villarreal-Garza, Cynthia
Ferrigno, Ana S.
Bretel, Denisse
Sala, Raul
Giacomazzi, Juliana
William, William N.
Werutsky, Gustavo
Current Scenario of Clinical Cancer Research in Latin America and the Caribbean
title Current Scenario of Clinical Cancer Research in Latin America and the Caribbean
title_full Current Scenario of Clinical Cancer Research in Latin America and the Caribbean
title_fullStr Current Scenario of Clinical Cancer Research in Latin America and the Caribbean
title_full_unstemmed Current Scenario of Clinical Cancer Research in Latin America and the Caribbean
title_short Current Scenario of Clinical Cancer Research in Latin America and the Caribbean
title_sort current scenario of clinical cancer research in latin america and the caribbean
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9858272/
https://www.ncbi.nlm.nih.gov/pubmed/36661699
http://dx.doi.org/10.3390/curroncol30010050
work_keys_str_mv AT gosslinggustavo currentscenarioofclinicalcancerresearchinlatinamericaandthecaribbean
AT rebelattotaianef currentscenarioofclinicalcancerresearchinlatinamericaandthecaribbean
AT villarrealgarzacynthia currentscenarioofclinicalcancerresearchinlatinamericaandthecaribbean
AT ferrignoanas currentscenarioofclinicalcancerresearchinlatinamericaandthecaribbean
AT breteldenisse currentscenarioofclinicalcancerresearchinlatinamericaandthecaribbean
AT salaraul currentscenarioofclinicalcancerresearchinlatinamericaandthecaribbean
AT giacomazzijuliana currentscenarioofclinicalcancerresearchinlatinamericaandthecaribbean
AT williamwilliamn currentscenarioofclinicalcancerresearchinlatinamericaandthecaribbean
AT werutskygustavo currentscenarioofclinicalcancerresearchinlatinamericaandthecaribbean